Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692374 | 1.00 | TUBB1 (0.61) | TUBB1 | |
| SCHEMBL57608 | 0.88 | TUBB1 (0.74) | TUBB1 | |
| SCHEMBL23394062 | 0.84 | TUBB1 (0.41) | TUBB1 | |
| SCHEMBL12202654 | 0.79 | TUBB1 (0.60) | TUBB1 | |
| SCHEMBL88548 | 0.77 | TUBB1 (0.74) | TUBB1 | |
| SCHEMBL13660108 | 0.77 | TUBB1 (0.74) | TUBB1 | |
| SCHEMBL58085 | 0.77 | TUBB1 (0.74) | TUBB1 | |
| SCHEMBL15434851 | 0.76 | TUBB1 (0.67) | TUBB1 | |
| SCHEMBL20732343 | 0.76 | TUBB1 (1.00) | TUBB1 | |
| SCHEMBL22308460 | 0.76 | TUBB1 (1.00) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238431-A1 | Bispecific Antibody-Drug Conjugate | BEIJING XUANZHU COMBIO CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238431-A1 | Bispecific Antibody-Drug Conjugate | BEIJING XUANZHU COMBIO CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-3892305-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | Sutro Biopharma, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238431-A1 | Bispecific Antibody-Drug Conjugate | BSG, DSG1, HASPIN | TUBB1 259/4885 |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | TUBB1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.